Targeting VEGF Pathway to Normalize the Vasculature: an Emerging Insight in Cancer Therapy

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2018 Nov 10

PMID 30410348

Citations 55

Authors

Jing-Biao Wu

Ya-Ling Tang

Xin-Hua Liang

Affiliations

Soon will be listed here.

Abstract

Vascular normalization is a new concept of targeting angiogenesis to restore vessel structure and function and to increase blood perfusion and delivery of drugs. It has been confirmed that vascular normalization can decrease relapse and benefit other cancer therapy, including chemotherapy, radiotherapy, and immune cell therapy. The key point of this therapy is to inhibit pro-angiogenic factors and make it be balanced with anti-angiogenic factors, resulting in a mature and normal vessel characteristic. Vascular endothelial growth factor (VEGF) is a key player in the process of tumor angiogenesis, and inhibiting VEGF is a primary approach to tumor vessel normalization. Herein, we review newly uncovered mechanisms governing angiogenesis and vascular normalization of cancer and place emphasis on targeting VEGF pathway to normalize the vasculature. Also, important methods to depress VEGF pathway and make tumor vascular are discussed.

Citing Articles

A Polymeric Vesicle System for Combined Lung Cancer Therapy through Chemotherapy and Vasculature Normalization.

Wang D, Qiu C, Chu Y, Zhang A, Huang R, Pan S Biomater Res. 2024; 28:0117.

PMID: 39606153 PMC: 11599482. DOI: 10.34133/bmr.0117.

The Complex Tumor Microenvironment in Ovarian Cancer: Therapeutic Challenges and Opportunities.

Garlisi B, Lauks S, Aitken C, Ogilvie L, Lockington C, Petrik D Curr Oncol. 2024; 31(7):3826-3844.

PMID: 39057155 PMC: 11275383. DOI: 10.3390/curroncol31070283.

The disruptive role of LRG1 on the vasculature and perivascular microenvironment.

Dritsoula A, Camilli C, Moss S, Greenwood J Front Cardiovasc Med. 2024; 11:1386177.

PMID: 38745756 PMC: 11091338. DOI: 10.3389/fcvm.2024.1386177.

Gene therapy in glioblastoma multiforme: Can it be a role changer?.

Rayati M, Mansouri V, Ahmadbeigi N Heliyon. 2024; 10(5):e27087.

PMID: 38439834 PMC: 10909773. DOI: 10.1016/j.heliyon.2024.e27087.

Nature's Elixir for Cancer Treatment: Targeting Tumor-induced Neovascularization.

Kumari R, Syeda S, Shrivastava A Curr Med Chem. 2024; 31(32):5281-5304.

PMID: 38425113 DOI: 10.2174/0109298673282525240222050051.

References

Zhou Q, Guo P, Gallo J . Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin Cancer Res. 2008; 14(5):1540-9. DOI: 10.1158/1078-0432.CCR-07-4544. View

Mukherjee T, Castelli-Gair Hombria J, Zeidler M . Opposing roles for Drosophila JAK/STAT signalling during cellular proliferation. Oncogene. 2005; 24(15):2503-11. DOI: 10.1038/sj.onc.1208487. View

van Solingen C, Seghers L, Bijkerk R, Duijs J, Roeten M, van Oeveren-Rietdijk A . Antagomir-mediated silencing of endothelial cell specific microRNA-126 impairs ischemia-induced angiogenesis. J Cell Mol Med. 2009; 13(8A):1577-85. PMC: 3828868. DOI: 10.1111/j.1582-4934.2008.00613.x. View

Konno H, Yamamoto M, Ohta M . Recent concepts of antiangiogenic therapy. Surg Today. 2010; 40(6):494-500. DOI: 10.1007/s00595-009-4150-2. View

Gerlowski L, Jain R . Microvascular permeability of normal and neoplastic tissues. Microvasc Res. 1986; 31(3):288-305. DOI: 10.1016/0026-2862(86)90018-x. View

Inglis D, Lavranos T, Beaumont D, Leske A, Brown C, Hall A . The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer. Cancer Biol Ther. 2014; 15(11):1552-60. PMC: 4622751. DOI: 10.4161/15384047.2014.956605. View

Jain R . Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001; 7(9):987-9. DOI: 10.1038/nm0901-987. View

Yu J, deMuinck E, Zhuang Z, Drinane M, Kauser K, Rubanyi G . Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve. Proc Natl Acad Sci U S A. 2005; 102(31):10999-1004. PMC: 1182413. DOI: 10.1073/pnas.0501444102. View

Rangwala F, Bendell J, Kozloff M, Arrowood C, Dellinger A, Meadows J . Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors. Invest New Drugs. 2014; 32(4):700-9. PMC: 4103954. DOI: 10.1007/s10637-014-0089-2. View

10.

Goel S, Wong A, Jain R . Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med. 2012; 2(3):a006486. PMC: 3282493. DOI: 10.1101/cshperspect.a006486. View

11.

Ye W . The Complexity of Translating Anti-angiogenesis Therapy from Basic Science to the Clinic. Dev Cell. 2016; 37(2):114-25. DOI: 10.1016/j.devcel.2016.03.015. View

12.

Matejuk A, Collet G, Nadim M, Grillon C, Kieda C . MicroRNAs and tumor vasculature normalization: impact on anti-tumor immune response. Arch Immunol Ther Exp (Warsz). 2013; 61(4):285-99. DOI: 10.1007/s00005-013-0231-4. View

13.

Willett C, Boucher Y, Tomaso E, Duda D, Munn L, Tong R . Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004; 10(2):145-7. PMC: 2693485. DOI: 10.1038/nm988. View

14.

Fire A, Xu S, Montgomery M, Kostas S, Driver S, Mello C . Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998; 391(6669):806-11. DOI: 10.1038/35888. View

15.

Choudhry H, Harris A, McIntyre A . The tumour hypoxia induced non-coding transcriptome. Mol Aspects Med. 2016; 47-48:35-53. DOI: 10.1016/j.mam.2016.01.003. View

16.

Manegold P, Paringer C, Kulka U, Krimmel K, Eichhorn M, Wilkowski R . Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer. Clin Cancer Res. 2008; 14(3):892-900. DOI: 10.1158/1078-0432.CCR-07-0955. View

17.

Niu G, Wright K, Huang M, Song L, Haura E, Turkson J . Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002; 21(13):2000-8. DOI: 10.1038/sj.onc.1205260. View

18.

Harper S, Bates D . VEGF-A splicing: the key to anti-angiogenic therapeutics?. Nat Rev Cancer. 2008; 8(11):880-7. PMC: 2613352. DOI: 10.1038/nrc2505. View

19.

Woolard J, Wang W, Bevan H, Qiu Y, Morbidelli L, Pritchard-Jones R . VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 2004; 64(21):7822-35. DOI: 10.1158/0008-5472.CAN-04-0934. View

20.

Cascio S, DAndrea A, Ferla R, Surmacz E, Gulotta E, Amodeo V . miR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells. J Cell Physiol. 2010; 224(1):242-9. DOI: 10.1002/jcp.22126. View